




Searching News Database: enoxaparin
HSMN NewsFeed - 25 Oct 2011
Lilly Announces Withdrawal of Xigris(R) Following Recent Clinical Trial Results
Lilly Announces Withdrawal of Xigris(R) Following Recent Clinical Trial Results
HSMN NewsFeed - 1 Feb 2011
Atherotech Diagnostics Lab Taps Mize as Vice President of Regulatory Affairs
Atherotech Diagnostics Lab Taps Mize as Vice President of Regulatory Affairs
HSMN NewsFeed - 5 Oct 2010
NormOxys, Inc. Appoints Dr. Gerard Riedel as Vice President, Regulatory Affairs and Program Management
NormOxys, Inc. Appoints Dr. Gerard Riedel as Vice President, Regulatory Affairs and Program Management
HSMN NewsFeed - 2 Sep 2008
New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients
New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients
HSMN NewsFeed - 26 Aug 2008
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology
HSMN NewsFeed - 9 Jul 2008
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
HSMN NewsFeed - 24 Jun 2008
Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
HSMN NewsFeed - 27 Mar 2008
Novel Oral Anticoagulant Pradaxa(R) (dabigatran etexilate) Approved by the European Commission
Novel Oral Anticoagulant Pradaxa(R) (dabigatran etexilate) Approved by the European Commission
HSMN NewsFeed - 4 Dec 2007
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
HSMN NewsFeed - 25 Oct 2007
Momenta Pharmaceuticals Announces Appointment of Jo-Ann Beltramello as Vice President, Human Resources
Momenta Pharmaceuticals Announces Appointment of Jo-Ann Beltramello as Vice President, Human Resources
HSMN NewsFeed - 24 Oct 2007
Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients
Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients
HSMN NewsFeed - 7 Aug 2007
The Medicines Company Submits Angiomax(R) (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
The Medicines Company Submits Angiomax(R) (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
HSMN NewsFeed - 18 May 2007
FDA Approves Lovenox(R) (Enoxaparin Sodium Injection) for the Most Severe Type of Heart Attack
FDA Approves Lovenox(R) (Enoxaparin Sodium Injection) for the Most Severe Type of Heart Attack
HSMN NewsFeed - 22 Nov 2006
The New England Journal of Medicine Publishes Angiomax(R) (Bivalirudin) ACUITY Trial Results
The New England Journal of Medicine Publishes Angiomax(R) (Bivalirudin) ACUITY Trial Results
Additional items found! 37

Members Archive contains
37 additional stories matching:
enoxaparin
(Password required)
enoxaparin
(Password required)